Monte Rosa Therapeutics, Inc. (GLUE) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
GLUE currently has 84.5M outstanding shares. with limited dilution risk as only 9.75M additional shares (11.5%) are authorized for issuance. The company has significantly diluted shareholders by 35.33% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 84.5M shares outstanding |
84M | 9.8M |
| Mar 17, 2026 |
10-K filing | 83.1M shares outstanding |
83M | 9.8M |
| Jan 07, 2026 |
8-K filing: Monte Rosa Therapeutics, Inc. terminated its sales agreement prospectus with Jefferies LLC but the Sales Agreement remains in effect; 2,955,082 shares of common stock were issued and sold under the Sales Agreement for $24.2 million in net proceeds. ($24.2M proceeds) |
65M | 9.8M |
| Nov 06, 2025 |
10-Q filing | 65.1M shares outstanding |
65M | 9.8M |
| Aug 07, 2025 |
10-Q filing | 61.8M shares outstanding |
62M | 9.8M |
| May 08, 2025 |
10-Q filing | 61.5M shares outstanding |
62M | 9.8M |
| Mar 20, 2025 |
10-K filing | 61.5M shares outstanding |
62M | 9.8M |
| Mar 20, 2025 |
S-3 filing: Monte Rosa Therapeutics, Inc. files an S-3 registration statement for a shelf offering of common stock, preferred stock, and debt securities up to $400,000,000. The company also files a prospectus supplement for an at-the-market offering of common stock up to $150,000,000 through Jefferies LLC. |
61M | 9.8M |
| Nov 07, 2024 |
10-Q filing | 61.4M shares outstanding |
61M | 9.8M |
| Aug 08, 2024 |
10-Q filing | 61.4M shares outstanding |
61M | 9.8M |
| May 09, 2024 |
10-Q filing | 50.5M shares outstanding |
51M | 9.8M |
| Mar 14, 2024 |
10-K filing | 51.4M shares outstanding |
51M | 9.8M |
| Nov 09, 2023 |
10-Q filing | 49.8M shares outstanding |
50M | 9.8M |
| Aug 10, 2023 |
10-Q filing | 49.4M shares outstanding |
49M | 9.8M |
| May 11, 2023 |
10-Q filing | 49.3M shares outstanding |
49M | 9.8M |
| Mar 16, 2023 |
10-K filing | 47.2M shares outstanding |
47M | 9.8M |
| Nov 10, 2022 |
10-Q filing | 46.7M shares outstanding |
47M | 9.8M |
| Aug 11, 2022 |
10-Q filing | 46.7M shares outstanding |
47M | 9.8M |
| Jul 01, 2022 |
S-3 filing: Monte Rosa Therapeutics, Inc. files an S-3 registration statement for a shelf offering of up to $300,000,000 in aggregate principal amount of common stock, preferred stock, and debt securities. The company also files for an ATM offering of common stock with Jefferies as the sales agent. |
47M | 9.8M |
| May 11, 2022 |
10-Q filing | 46.7M shares outstanding |
47M | 9.8M |
| Mar 29, 2022 |
10-K filing | 46.6M shares outstanding |
47M | 9.8M |
| Nov 10, 2021 |
10-Q filing | 46.5M shares outstanding |
47M | 9.8M |
| Aug 12, 2021 |
10-Q filing | 46.4M shares outstanding |
46M | 9.8M |
| Jun 21, 2021 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock, with J.P. Morgan acting as one of the underwriters. The company intends to use the net proceeds from the offering to fund the development of its GSPT1 program and for working capital. |
43M | 9.8M |
| Jun 09, 2021 |
S-1/A filing: S-1/A filing for an offering of common stock. |
6.1M | 0 |
| Jun 04, 2021 |
S-1 filing: This is an S-1 filing for an initial public offering of common stock, with J.P. Morgan, Cowen, Piper Sandler and Guggenheim Securities as underwriters. It details the terms of the offering, including the number of shares outstanding, potential proceeds, and use of proceeds, also covers risk factors, and includes financial information from 2019-2021. |
6.1M | 0 |